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valve-sparing root replacement, reimplantation was associ-
ated with a reduced rate of reintervention compared with
remodelling (0.7%/year vs. 2.4%/year, p = 0.02). 
Conclusions: Valve-sparing root replacement may represent a
valuable option for patients with Marfan syndrome who
require surgery for aortic aneurysm, but should be used with
caution in patients with valve characteristics at risk for
decreased durability. 
Perspective: As with mitral valve repair, a well-performed
aortic valve repair might be better than aortic valve replace-
ment. However, a well-performed valve replacement
probably is better than a poorly performed valve repair. If
valve-sparing aortic root replacement is better than total
root replacement, then there is a rationale for referral of
patients with Marfan syndrome and aortic root aneurysm to
a surgeon and a center where valve-sparing root repair is
routinely performed.
Summary written by: David S. Bach, MD
Impact of Prosthesis-Patient Mismatch After Mitral
Valve Replacement: A Multicentre Analysis of Early
Outcomes and Mid-Term Survival
Shi WY, Yap CH, Hayward PA, et al.
Heart 2011;97:1074-1081.
Study Question: Does prosthesis-patient mismatch (PPM)
after mitral valve replacement impact clinical outcome? 
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Surgical Management of Aortic Root Disease in
Marfan Syndrome: A Systematic Review and Meta-
Analysis
Benedetto U, Melina G, Takkenberg JJ, Roscitano A, Angeloni E,
Sinatra R.
Heart 2011;97:955-958.
Study Question: How do the results of total root replacement
compare with valve-sparing aortic root replacement in
patients with Marfan syndrome? 
Methods: A meta-analysis was performed, searching PubMed,
Embase, and Cochrane library for papers published between
January 1966 and February 2010 reporting on aortic root
operations in patients with Marfan syndrome. Of the 530
studies retrieved, 11 were utilized (observational studies with
sample size ≥30 that reported valve-related morbidity and
mortality after total root replacement and/or valve-sparing
root replacement in patients with Marfan syndrome). The
two surgical procedures were analyzed separately. 
Results: Overall, 1,385 patients were analyzed (972 had total
root and 413 valve-sparing root replacement). Re-interven-
tion rate was 0.3%/year versus 1.3%/year (p = 0.02) and the
thromboembolic event rate was 0.7%/year versus 0.3%/year
(p = 0.01) after total root and valve-sparing root replace-
ment, respectively. When composite valve-related events
were compared, no difference existed between the two surgi-
cal strategies (p = 0.41). Among patients undergoing
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Methods: A prospective study was performed at a single insti-
tution. As part of standard of care, 100 consecutive patients
underwent DSCT prior to repair of tetralogy of Fallot, in
addition to routine echocardiography. A helical protocol was
used for 42 patients, and a prospective sequential protocol
was used in 58. 
Results: The median age at repair was 6.8 months. Coronary
artery abnormalities were noted in seven patients. Compared
with surgical findings, DSCT had a sensitivity and speci-
ficity of 100% for detection of coronary artery abnormalities.
The mean effective radiation dose for the prospective
sequential protocol was relatively low at 0.46 mSv, as com-
pared with 1.49 mSv for the helical protocol. Coronary
abnormalities included anomalous left anterior descending
artery arising from the right coronary artery in four patients,
and a single coronary artery in three. 
Conclusions: DSCT is an accurate and noninvasive tool for
delineating coronary artery abnormalities prior to surgical
intervention in children with tetralogy of Fallot. DSCT
might be used in place of coronary angiography and in com-
bination with echo studies to evaluate coronary anatomy
prior to tetralogy repair.  
Perspective: This study shows excellent accuracy of coronary
CT in 100 patients undergoing surgical repair of tetralogy of
Fallot. Because of the high risk of exposure to ionizing radi-
ation in young patients, routine preoperative coronary CT is
not justifiable. DSCT should be reserved for patients in
whom the echocardiogram has not adequately diagnosed
coronary anomalies, and coronary angiography may have
been considered for definitive diagnosis.
Summary written by: Timothy B. Cotts, MD
General
Utility of Absolute and Relative Changes in Cardiac
Troponin Concentrations in the Early Diagnosis of
Acute Myocardial Infarction
Reichlin T, Irfan A, Twerenbold R, et al.
Circulation 2011;124:136-145.
Study Question: Are early absolute rises in cardiac troponin
(cTn) concentrations using a high-sensitivity (hs) assay bet-
ter than relative rises in cTn for diagnosis of acute
myocardial infarction (AMI)? 
Methods: The diagnostic accuracy of absolute and relative (%)
changes in cTn were determined in 836 patients presenting
to the emergency room with symptoms suggestive of AMI.
Blood samples for the determination of hs cTnT and cTnI
ultra were collected at presentation and after 1 and 2 hours
in a blinded fashion. The final diagnosis was adjudicated by
two independent cardiologists.  
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Methods: From 2001 to 2009, 1,006 mechanical and biopros-
thetic mitral valves were implanted across 10 institutions in
Australia. Effective orifice areas (EOAs) were obtained
from a literature review of in vivo echocardiographic data.
Absent, moderate, and severe PPM were defined as indexed
EOA (EOA/body surface area) of >1.20 cm2/m2, >0.90 to
≤1.20 cm2/m2, and ≤0.9 cm2/m2, respectively. 
Results: PPM was absent in 34%, moderate in 53%, and
severe in 13% of patients. Patients with PPM were more
likely to be male (42% vs. 52% vs. 62%, p < 0.0001) and
obese (14% vs. 20% vs. 56%, p < 0.0001). Postoperatively,
there were similar 30-day mortalities (5% vs. 5% vs. 6%, p =
0.83) and early all-cause mortality/morbidity (24% vs. 27%
vs. 29%, p = 0.40). Seven-year survival was similar between
groups (72 ± 4.1% vs. 76 ± 3.2% vs. 69 ± 10.3%, p = 0.76).
PPM did not predict adverse events after logistic and Cox
regressions with and without propensity score adjustment.
Subgroup analyses of those with isolated mitral valve sur-
gery, patients with preoperative congestive heart failure, and
nonobese patients failed to show an association between
PPM and mid-term mortality. 
Conclusions: Overall, PPM was not associated with poorer
early outcomes or mid-term survival. Oversizing valves may
be technically hazardous, and does not yield superior out-
comes. Easier implantation by appropriate sizing appears to
be justified.
Perspective: Methodologically, the use of published reference
standards for prosthesis EOA is problematic, owing to sub-
stantial variation between patients. In light of challenges in
reliably obtaining valve area and long-term follow-up in large
groups of patients after valve replacement, along with con-
founding comorbid conditions, whether PPM (mitral or
aortic) definitively is an independent risk for excess mortality
after valve replacement likely will remain a topic of con-
tention.
Summary written by: David S. Bach, MD
Congenital Heart Disease
Diagnostic Accuracy of Dual-Source Multislice
Computed Tomographic Analysis for the
Preoperative Detection of Coronary Artery
Anomalies in 100 Patients With Tetralogy of Fallot
Vastel-Amzallag C, Le Bret E, Paul JF, et al.
J Thorac Cardiovasc Surg 2011;142:120-126.
Study Question: What is the accuracy of dual-source com-
puted tomography (DSCT) for diagnosis of coronary
anomalies prior to surgical repair of tetralogy of Fallot in
infants and children? 
smoking is ~10. Assuming a baseline risk of serious adverse
CV events of 5.57% per year (among smokers with stable
CV disease), the number needed to harm (to cause one
additional serious CV event) with varenicline is ~28 per
year. The number of deaths was inadequate to assess effect
of varenicline on mortality. 
Conclusions: The meta-analysis raises safety concerns about
the potential for an increased risk of serious adverse CV
events associated with the use of varenicline among tobacco
users. 
Perspective: The Food and Drug Administration has placed a
'black box' warning for varenicline that includes increase in
risk for CV events in relatively short-term studies. Other
potential serious adverse events include neuropsychiatric
symptoms such as depressed mood, agitation, and suicidal
thoughts. Long-term adverse effects of varenicline need to
be assessed prior to advocating chronic use.   
Summary written by: Melvyn Rubenfire, MD
Ticagrelor Compared With Clopidogrel by
Geographic Region in the Platelet Inhibition and
Patient Outcomes (PLATO) Trial
Mahaffey KW, Wojdyla DM, Carroll K, et al.; on behalf of the
PLATO Investigators.
Circulation 2011;Jun 27:[Epub ahead of print].
Study Question: What are the reasons for the observed geo-
graphic variation in outcome associated with use of
ticagrelor in the PLATO trial?  
Methods: The authors performed a post-hoc analysis to assess
the geographic variation in outcome in the PLATO trial,
where the use of ticagrelor was associated with worse out-
come in patients in the United States, whereas a significant
benefit was observed among the rest of the patients. Cox
regression analyses were performed to quantify how much of
the regional interaction could be explained by patient charac-
teristics and concomitant treatments, including aspirin
maintenance therapy.  
Results: The analysis ruled out systematic error. Possibility of
it being a chance finding could not be definitively excluded.
More patients in the United States (53.6%) than in the rest
of the world (1.7%) took a median aspirin dose ≥300 mg/d.
A total of 37 baseline and postrandomization factors were
explored, and only aspirin dose explained a substantial frac-
tion of the regional interaction. In adjusted analyses, among
patients taking low-dose maintenance aspirin, ticagrelor was
associated with better outcomes compared with clopidogrel,
with statistical superiority in the rest of the world and
similar outcomes in the US cohort. 
Results: The area under the receiver operating characteristic
(ROC) curve for diagnosing AMI was significantly higher
for 2-hour absolute versus 2-hour relative (%) cTn changes
([95% CI], hs cTnT, 0.95 [0.92-0.98] vs. 0.76 [0.70-0.83],
p < 0.001; cTnI ultra, 0.95 [0.91-0.99] vs. 0.72 [0.66-0.79],
p < 0.001). The ROC–derived cutoff value for 2-hour
absolute change was 0.007 μg/L for hs cTnT and 0.020
μg/L for cTnI ultra. Absolute changes were superior to rela-
tive changes in patients with both low and elevated baseline
cTn levels. 
Conclusions: Absolute changes of cTn levels have a signifi-
cantly higher diagnostic accuracy for AMI than relative
changes, and seem, therefore, to be the preferred criteria to
distinguish AMI from other causes of cTn elevations. 
Perspective: The rise and fall of the cTn level are important in
establishing the proper diagnosis of AMI. Criteria for a
‘positive’ rise are not established. This study demonstrates
that absolute changes, regardless of baseline Tn level, are
more useful than relative changes of cTn in confirming the
diagnosis of MI. The cutoff value for significant rise is
approximately one half the 99% values for the assays used in
this study.  
Summary written by: Daniel T. Eitzman, MD
Risk of Serious Adverse Cardiovascular Events
Associated With Varenicline: A Systematic Review
and Meta-Analysis
Singh S, Loke YK, Spangler JG, Furberg CD.
CMAJ 2011;Jul 4:[Epub ahead of print].
Study Question: Are there serious adverse cardiovascular (CV)
effects of varenicline among tobacco users?
Methods: The authors conducted a review of adverse CV
effects of varenicline in published data, websites of regula-
tory authorities, and registries of clinical trials through
September 2010 for published and unpublished studies.
Study eligibility included double-blind randomized con-
trolled trials of at least 1-week duration involving smokers
or people who used smokeless tobacco that reported on CV
events (ischemia, arrhythmia, congestive heart failure, sud-
den death, or CV-related death) as serious adverse events
associated with the use of varenicline. 
Results: A total of 14 trials were selected, involving 8,216
subjects. Trials ranged from 7-52 weeks. Varenicline was
associated with a significantly increased risk of serious
adverse CV events compared with placebo (1.06%
[52/4,908] in the varenicline group vs. 0.82% [27/3,308] in
the placebo group; Peto odds ratio 1.72, 95% confidence
interval 1.09-2.71). The number needed to treat with
varenicline for one additional person to successfully quit




Conclusions: The result of this analysis suggests that the
observed regional interaction in the PLATO trial could arise
from chance alone or could be explained by an underlying sta-
tistical interaction with aspirin maintenance dose. The lowest
risk of cardiovascular death, myocardial infarction, or stroke
with ticagrelor compared with clopidogrel was observed in
patients on a low maintenance dose of concomitant aspirin. 
Perspective: While there is no good reason to use a higher
maintenance dose of aspirin in patients on ticagrelor (or clopi-
dogrel), one must be cautious about overinterpreting subgroup
analysis (ISIS-2, Lancet 1988). I cannot imagine this variation
would have received the same degree of scrutiny if this finding
related to some other region of the world, or reflected a sub-
group that did not have regulatory implications.
Summary written by: Hitinder S. Gurm, MBBS
Quality of Care and Patient Outcomes in Critical
Access Rural Hospitals
Joynt KE, Harris Y, Orav EJ, Jha AK.
JAMA 2011;306:45-52.
Study Question: What is the quality of care provided by critical
access hospitals (CAHs) and the outcomes their patients
achieve? 
Methods: This was a retrospective analysis in 4,738 US hos-
pitals of Medicare fee-for-service beneficiaries with acute
myocardial infarction (AMI) (10,703 for CAHs vs. 469,695
for non-CAHs), congestive heart failure (CHF) (52,927 for
CAHs vs. 958,790 for non-CAHs), and pneumonia (86,359
for CAHs vs. 773,227 for non-CAHs) who were discharged
in 2008-2009. The main outcome measures were clinical
capabilities, performance on processes of care, and 30-day
mortality rates, adjusted for age, sex, race, and medical
comorbidities. 
Results: Compared with other hospitals (n = 3,470), 1,268
CAHs (26.8%) were less likely to have intensive care units
(30.0% vs. 74.4%, p < 0.001), cardiac catheterization capa-
bilities (0.5% vs. 47.7%, p < 0.001), and at least basic
electronic health records (6.5% vs. 445 13.9%, p < 0.001).
The CAHs had lower performance on processes of care
than non-CAHs for all three conditions examined (concor-
dance with Hospital Quality Alliance process measures for
AMI, 91.0% vs. 97.8%; for CHF, 80.6% vs. 93.5%; and for
pneumonia, 89.3% vs. 93.7%; p < 0.001 for each). Patients
admitted to CAHs had higher 30-day mortality rates for
each condition than those admitted to non-CAHs (for
AMI: 23.5% vs. 16.2%; p < 0.001; for CHF: 13.4% vs.
10.9%; p < 0.001; and for pneumonia: 14.1% vs. 12.1%;
p < 0.001). 
Conclusions: CAHs had fewer clinical capabilities, worse
measured processes of care, and higher mortality rates for
patients with AMI, CHF, or pneumonia. 
Perspective: These findings should serve as a stimulus to help
CAHs improve the quality of care they provide so that all
individuals in the United States have access to high-quality
inpatient and outpatient care regardless of where they live.
One strategy for improving quality would be to develop net-
works of CAHs for the purposes of sharing resources,
education, experience, and promoting operational efficiencies.
Summary written by: Debabrata Mukherjee, MD
Effect of Fibroblast Growth Factor NV1FGF on
Amputation and Death: A Randomised Placebo-
Controlled Trial of Gene Therapy in Critical Limb
Ischaemia
Belch J, Hiatt WR, Baumgartner I, et al.; on behalf of the TAMARIS
Committees and Investigators.
Lancet 2011;377:1929-1937.
Study Question: What is the impact of nonviral 1 fibroblast
growth factor (NV1FGF) injections on amputation-free sur-
vival in patients with severe peripheral vascular disease?
Methods: The authors randomized 525 patients with critical
limb ischemia unsuitable for revascularization to either
NV1FGF 0.2 mg/ml or matching placebo. All patients had
ischemic ulcer in their legs or minor skin gangrene and met
hemodynamic criteria. Randomization was stratified by dia-
betes status and country. Patients received eight
intramuscular injections of their assigned treatment in the
index leg on days 1, 15, 29, and 43. The primary endpoint
was time to major amputation or death at 1 year.  
Results: The study assigned 259 patients to NV1FGF and
266 patients to placebo. The mean age of the cohort was 70
years and 53% were diabetic. There was no difference in the
primary endpoint (33% vs. 36%; hazard ratio, 1.11; p = 0.48)
or components of the primary endpoint between treatment
groups. There was no difference in side effects between the
two groups. 
Conclusions: NV1FGF is ineffective for reduction of amputation
or death in patients with critical limb ischemia. 
Perspective: This study adds to the list of failed gene strategies
that have been evaluated for treatment of critical limb
ischemia. Better utilization of primary and secondary preven-
tive therapies upstream may be a more effective strategy at
reducing the mortality and morbidity associated with advanced
peripheral arterial disease, and remains woefully inadequate in
this patient population. 
Summary written by: Hitinder S. Gurm, MBBS
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Appropriateness of Percutaneous Coronary
Intervention
Chan PS, Patel MR, Klein LW, et al.
JAMA 2011;306:53-61.
Study Question: What is the appropriateness of percutaneous
coronary intervention (PCI) in contemporary practice? 
Methods: The authors assessed the appropriateness of PCI
among patients undergoing PCI between July 1, 2009, and
September 30, 2010, at 1,091 hospitals enrolled in the
NCDR®. Using the appropriate use criteria for coronary
revascularization, all procedures were classified as appropri-
ate, inappropriate, or uncertain. Analysis was stratified by
whether the procedure was performed for an acute (ST-seg-
ment elevation myocardial infarction, non–ST-segment
elevation myocardial infarction, or unstable angina with
high-risk features) or nonacute indication. 
Results: The study cohort was comprised of 500,154 proce-
dures, of which 355,417 were for acute indications. The
overall use of inappropriate PCI was low and mostly
restricted to nonacute indications. Among patients with
acute indication for PCI, 98.6% were classified as appropri-
ate, 0.3% as uncertain, and 1.1% as inappropriate. For
nonacute indications, 50.4% were classified as appropriate,
38.0% as uncertain, and 11.6% as inappropriate. The major-
ity of inappropriate PCIs for nonacute indications were
performed in patients with no angina (53.8%), low-risk
ischemia on noninvasive stress testing (71.6%), or suboptimal
(≤1 medication) antianginal therapy (95.8%). There was sub-
stantial hospital variation for nonacute procedures (median
hospital rate for inappropriate PCI, 10.8%). 
Conclusions: Almost all of the PCIs performed in the United
States for acute reasons were appropriate, whereas approxi-
mately 10-12% of those performed for nonacute reasons were
classified as inappropriate.
Perspective: Appropriateness use criteria are based only par-
tially on hard evidence and are derived using expert
consensus, and some disagreement is to be expected. Further,
these criteria assume stress testing to be infallible, and basing
appropriateness of PCI on a test with less than perfect sensi-
tivity and specificity would automatically introduce a level of
disagreement that cannot be avoided. I doubt any operator or
institution could have total absence of inappropriate PCI
using these criteria, and the best use of these criteria would
be to assess the practice patterns at institutions that deviate
significantly from the mean (in either direction).
Summary written by: Hitinder S. Gurm, MBBS
Interventional
Effect of Upstream Clopidogrel Treatment in
Patients With ST-Segment Elevation Myocardial
Infarction Undergoing Primary Percutaneous
Coronary Intervention
Koul S, Smith JG, Scherstén F, James S, Lagerqvist B, Erlinge D.
Eur Heart J 2011;Jun 30:[Epub ahead of print].
Study Question: What are the long-term clinical outcomes of
upstream clopidogrel treatment in patients undergoing pri-
mary percutaneous coronary intervention (PCI) for
ST-segment elevation myocardial infarction (STEMI)? 
Methods: All patients who underwent PCI for STEMI in
Sweden between 2003 and 2008 were identified from the
national Swedish Coronary Angiography and Angioplasty
Registry. Patients with concomitant warfarin treatment and
patients not having received aspirin upstream were excluded,
leaving 13,847 patients for the analysis. Groups were com-
pared for death and MI during 1 year of follow-up using
Cox regression models with adjustment for differences in
baseline characteristics by propensity score methods.
Results: The combined primary endpoint of death or MI
during 1-year follow-up occurred in 1,325 of 9,813 patients
with upstream clopidogrel and in 364 of 4,034 patients
without. After propensity score adjustment, a significant rel-
ative risk reduction (hazard ratio [HR], 0.82) in death/MI
at 1 year was observed. The secondary endpoint of total 1-
year death was significantly reduced (HR, 0.76), while the
incidence of 1-year MI did not show any significant reduc-
tion (HR, 0.90). Similar results were observed in
multivariate analysis on top of propensity scoring and in
sensitivity analyses excluding patients without clopidogrel
and aspirin at discharge.  
Conclusions: Upstream clopidogrel treatment prior to arrival at
the catheterization lab is associated with a reduction in the
combined risk of death or MI as well as death alone in
patients with STEMI treated with primary PCI. 
Perspective: This large observational study indicates a potential
beneficial effect of early administered clopidogrel in patients
with STEMI treated with primary PCI. The benefits were
shown both at 30 days as well as 1 year for both endpoints.
Despite the limitations of an observational study, these find-
ings appear to support current guideline recommendations
regarding as early as possible clopidogrel administration in the
setting of STEMI.
Summary written by: Debabrata Mukherjee, MD





Co-Stimulation Modulation With Abatacept in
Patients With Recent-Onset Type 1 Diabetes: A
Randomised, Double-Blind, Placebo-Controlled
Trial
Orban T, Bundy B, Becker DJ, et al.
Lancet 2011;378:412-419.
Study Question: Does modulation of T-cell activation with
abatacept in patients with type 1 diabetes mellitus (DM)
lead to preservation of pancreatic β-cell function? 
Methods: Patients ages 6-45 years recently diagnosed with
type 1 diabetes were randomly assigned (2:1) to receive abat-
acept (10 mg/kg, maximum 1000 mg per dose) or placebo
infusions intravenously on days 1, 14, 28, and monthly for a
total of 27 infusions over 2 years. The primary outcome was
2-hour area-under-the-curve (AUC) serum C-peptide con-
centration after a mixed-meal tolerance test at 2-year
follow-up. 
Results: A total of 112 patients were assigned to treatment
groups (77 abatacept, 35 placebo). Adjusted C-peptide
AUC was 59% higher at 2 years with abatacept (0.378
nmol/L) than with placebo (0.238 nmol/L; p = 0.0029).
The difference between groups was present throughout the
trial, with an estimated 9.6-month delay in C-peptide
reduction with abatacept. 
Conclusions: Co-stimulation modulation with abatacept
slowed reduction in β-cell function over 2 years. The benefi-
cial effect suggests that T-cell activation still occurs around
the time of clinical diagnosis of type 1 diabetes. 
Perspective: Type 1 DM is typically due to autoimmune-
mediated destruction of pancreatic beta-cells. Preservation
of residual beta-cell function at diagnosis could reduce dia-
betic complications. Thus, therapies to reduce the
autoimmune response may benefit these patients. Abatacept
inhibits the co-stimulation of T-cells and has been shown to
be beneficial in some rheumatologic diseases and to prevent
diabetes in a mouse model. This study suggests that there
are ongoing T-cell-mediated effects on beta-cell function at
the time of type 1 DM diagnosis and that insulin secretion
can be preserved if these effects are blocked. Whether the
apparent early benefit of this treatment on beta-cell function
will translate into meaningful long-term benefits will require
additional studies.
Summary written by: Daniel T. Eitzman, MD
Prevention/Vascular
Cost-Effectiveness of Statin Therapy for Primary
Prevention in a Low-Cost Statin Era
Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K,
Goldman L.
Circulation 2011;124:146-153. 
Study Question: Are expanded statin prescribing strategies
using low-cost generics cost-effective for primary preven-
tion?
Methods: Expanded statin prescribing strategies were simu-
lated with a coronary heart disease (CHD) policy model.
This model is an established computer simulation, Markov
state-transition model of CHD incidence, prevalence, mor-
tality, and costs in the US population >35 years of age. The
model simulates development of CHD and associated events
in the US population stratified by age, sex, diastolic blood
pressure, smoking status, high-density lipoprotein choles-
terol, low-density lipoprotein (LDL) cholesterol, diabetes
mellitus, and use of statin therapy. Costs and quality-
adjusted life-years (QALYs) were discounted at 3% per year.
The model created assumed that a low-intensity statin inter-
vention would reduce LDL by 27%, which translates into an
8-34% relative risk reduction depending on age.
Results: Based on an estimated statin cost of $4 dollars per
month, treatment thresholds of LDL cholesterol >160
mg/dl for low-risk (0-1 risk factor), >130 mg/dl for moder-
ate-risk (≥2 risk factors and 10-year risk >10%), and >100
mg/dl for moderately high-risk persons (≥2 risk factors and
10-year risk >10%) would reduce annual health care costs by
$430 million compared with Adult Treatment Panel III
guidelines. Lowering thresholds to >130 mg/dl for persons
with zero risk factors and >100 mg/dl for persons with one
risk factor and treating all moderate- and moderately high-
risk persons regardless of LDL cholesterol would provide
additional health benefits for $9,900 per QALY. 
Conclusions: Low-cost statins are cost-effective for most per-
sons with even modestly elevated cholesterol or any CHD risk
factors if they do not mind taking a pill daily. Adverse effects
are unlikely to outweigh benefits in any subgroup in which
statins are found to be efficacious.
Perspective: This is an interesting study, which adds to the
debate about prescribing and paying for lipid-lowering ther-
apies such as statins among patients with modestly elevated
cholesterol. Whether such studies can or should impact pre-
vention guidelines remains unclear.
Summary written by: Elizabeth A. Jackson, MD
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Smoking Cessation Support Delivered Via Mobile
Phone Text Messaging (txt2stop): A Single-Blind,
Randomised Trial
Free C, Knight R, Robertson S, et al.
Lancet 2011;378:49-55.
Study Question: What are the effects of a mobile phone text-
messaging smoking cessation program on biochemically
verified continuous smoking abstinence for 6 months? 
Methods: The authors reported the results of a single-blind,
randomized trial of smoking cessation advice and support
conducted via mobile phone text messages between October
15, 2007 and June 1, 2009, among smokers willing to make
a quit attempt who were ages 16 years or older and
responded to an advertised solicitation to participate.
Participants were randomized to a smoking cessation pro-
gram (txt2stop) or to a control group of text messages
unrelated to quitting. Participants set a quit date within 2
weeks of randomization, and then received five text mes-
sages a day for the first 5 weeks, and three a day for the next
26 weeks. The primary outcome was self-reported continu-
ous smoking abstinence, biochemically verified at 6 months
based on intention to treat. Salivary cotinine testing was
used to verify self-reported abstinence at 6 months, with a
cutoff of 7 ng/ml of cotinine.
Results: The authors assessed 11,914 volunteers for eligibil-
ity, and randomized 5,800, of whom 2,915 were allocated to
the intervention and 2,885 to the control group. Outcome
data were available for 95% of participants. In 6 months,
significantly more subjects in the txt2stop group had bio-
chemically verified continuous abstinence, compared with
controls (10.7% vs. 4.9%). There was no significant hetero-
geneity shown in any of the prespecified subgroups, based
on age, employment type, Fagerstrom score, or use of other
smoking cessation products or services. The results were
similar when participants lost to follow-up were treated as
smokers in the analysis (9% vs. 4%), as well as if those lost
to follow-up were excluded (10% vs. 4%). 
Conclusions: The txt2stop smoking cessation program signifi-
cantly improved smoking cessation rates at 6 months. This
program should be considered for inclusion in smoking cessa-
tion services. 
Perspective: Regardless of the subgroup analyzed in this study,
the authors demonstrated a more than doubling of the rate of
biochemically verified, sustained smoking cessation at 6
months. Although these impressive relative results should
inspire optimism, as should the potentially additive effect of
this text messaging intervention on top of other smoking
cessation approaches, note that the absolute success rate
reported (10.7% verified abstinence at 6 months) suggests that
the resistance of tobacco addiction still lacks the sought-after
panacea.
Summary written by: James B. Froehlich, MD, MPH
Adherence to a Low-Risk, Healthy Lifestyle and
Risk of Sudden Cardiac Death Among Women
Chiuve SE, Fung TT, Rexrode KM, et al.
JAMA 2011;306:62-69.
Study Question: Does a healthy lifestyle lower risk for sudden
cardiac death (SCD) among women? Data from the Nurses’
Health Study were used for the present analysis. Data on
lifestyle factors assessed through questionnaires (every 2-4
years) from June 1984 to June 2010 were collected and a
low-risk lifestyle was defined as not smoking, body mass
index of less than 25, exercise duration of 30 minutes/day or
longer, and top 40% of the alternate Mediterranean diet
score. The Mediterranean diet score emphasized high intake
of vegetables, fruits, nuts, legumes, whole grains, and fish
and moderate intake of alcohol. The outcome of interest
was SCD.
Results: A total of 81,722 US women were included. During
the 26 years of follow-up, 321 cases of SCD were identified.
Women were a mean age of 72 years at the time of the SCD
event. All four low-risk lifestyle factors were significantly and
independently associated with a lower risk of SCD. The
absolute risks of SCD were 22 cases/100,000 person-years
among women with 0 low-risk factors, 17 cases with one, 18
cases with two, 13 cases with three, and 16 cases/100,000 per-
son-years with four low-risk factors. Compared with women
with 0 low-risk factors, the multivariable relative risk of SCD
was 0.54 for women with one low-risk factor, 0.41 for two,
0.33 for three, and 0.08 for four low-risk factors. The propor-
tion of SCD attributable to smoking, inactivity, overweight,
and poor diet was 81%. Among women without clinically
diagnosed coronary heart disease, the percentage of popula-
tion-attributable risk was 79%. 
Conclusions: Adherence to a low-risk lifestyle is associated with
a low risk of SCD. 
Perspective: Prior work has demonstrated significant reduc-
tions in risk of heart disease and diabetes with lifestyle. This
current study adds evidence for the benefits of lifestyle in
prevention of SCD.
Summary written by: Elizabeth A. Jackson, MD




National, Regional, and Global Trends in Fasting
Plasma Glucose and Diabetes Prevalence Since
1980: Systematic Analysis of Health Examination
Surveys and Epidemiological Studies With 370
Country-Years and 2.7 Million Participants
Danaei G, Finucane MM, Lu Y, et al., on behalf of the Global
Burden of Metabolic Risk Factors of Chronic Diseases
Collaborating Group (Blood Glucose).
Lancet 2011;378:31-40.
Study Question: What are the trends in mean fasting plasma
glucose (FPG) and diabetes prevalence for adults ages 25
years and older in 199 countries and territories? 
Methods: The investigators obtained data from health exami-
nation surveys and epidemiological studies (370 country-years
and 2.7 million participants). They converted systematically
between different glycemic metrics. For each sex, they used a
Bayesian hierarchical model to estimate mean FPG and its
uncertainty by age, country, and year, accounting for whether
a study was nationally, subnationally, or community represen-
tative. FPG trends over time were modeled as a linear trend
plus a smooth nonlinear trend, at all levels. 
Results: In 2008, global age-standardized mean FPG was
5.50 mmol/L for men and 5.42 mmol/L for women, having
risen by 0.07 mmol/L and 0.09 mmol/L per decade, respec-
tively. Age-standardized adult diabetes prevalence was 9.8%
in men and 9.2% in women in 2008, up from 8.3% and
7.5% in 1980. The number of people with diabetes
increased from 153 million in 1980, to 347 million in 2008.
The investigators recorded almost no change in mean FPG
in east and southeast Asia and central and eastern Europe.
Oceania had the largest rise, and the highest mean FPG
and diabetes prevalence in 2008. Mean FPG and diabetes
prevalence in 2008 were also high in south Asia, Latin
America and the Caribbean, and central Asia, north Africa,
and the Middle East. Mean FPG in 2008 was lowest in
sub-Saharan Africa, east and southeast Asia, and high-
income Asia-Pacific. In high-income subregions, western
Europe had the smallest rise; North America the largest.   
Conclusions: Glycemia and diabetes are rising globally, driven
both by population growth and ageing and by increasing age-
specific prevalences. 
Perspective: This systematic analysis shows that glycemia and
diabetes are a rising global hazard, with the number of adults
with diabetes having more than doubled over nearly three
decades. Although population growth and ageing are impor-
tant contributors to this increase, there is also an important
epidemiological component, with age-standardized global
mean FPG having increased by 0.07 mmol/L per decade. 
Summary written by: Debabrata Mukherjee, MD
Terutroban Versus Aspirin in Patients With
Cerebral Ischaemic Events (PERFORM): A
Randomised, Double-Blind, Parallel-Group Trial
Bousser MG, Amarenco P, Chamorro A, et al.; on behalf of the
PERFORM Study Investigators.
Lancet 2011;377:2013-2022.
Study Question: What is the safety and efficacy of terutroban
compared with aspirin in the prevention of cerebral and
cardiovascular ischemic events in patients with a recent
noncardioembolic cerebral ischemic event? 
Methods: PERFORM was a randomized, double-blind, paral-
lel-group trial performed at 802 centers in 46 countries. The
trial randomized patients who had an ischemic stroke in the
previous 3 months or a transient ischemic attack in the pre-
vious 8 days to 30 mg per day of terutroban or 100 mg per
day of aspirin. The primary efficacy endpoint was a compos-
ite of fatal or nonfatal ischemic stroke or myocardial
infarction (MI), or other vascular death. The study was
stopped prematurely for futility.
Results: The study randomized 9,562 patients to terutroban
and 9,558 to aspirin. The mean follow-up was 28 months.
There was no difference in the primary endpoint between
the two arms (11% vs. 11%; hazard ratio [HR],1.02; 95%
confidence interval [CI], 0.94-1.12). There was an increase
in minor bleeding with terutroban compared with aspirin
(12% vs. 11%; HR, 1.11; 95% CI, 1.02-1.21), but no sig-
nificant differences in other safety endpoints were noted.
Conclusions: The trial did not meet the predefined criteria for
noninferiority, but showed similar rates of the primary end-
point with terutroban and aspirin, without any safety or
efficacy advantage for terutroban.
Perspective: Terutroban joins many other agents that have
failed to demonstrate a clinically relevant advantage over
aspirin for secondary prevention in patients with prior cere-
bral events. These patients have a high risk of future adverse
events with a nearly 5% annual risk of stroke, MI, or death
and a 3.5% risk of stroke, and there remains a need to define
strategies that can reduce this risk further.
Summary written by: Hitinder S. Gurm, MBBS
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